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Available online 23 December 2015Parathyroid hormone (PTH) is secreted from the parathyroid glands in response to low plasma calcium levels.
Besides its classical actions on bone and kidney, PTH may have other important effects, including metabolic
effects, as suggested for instance by increased prevalence of insulin resistance and type 2 diabetes in patients
with primary hyperparathyroidism. Moreover, secondary hyperparathyroidismmay contribute to the metabolic
derangements that characterize states of vitamin D deﬁciency. PTH has been shown to induce adipose tissue
lipolysis, but the details of the lipolytic action of PTH have not been described. Here we used primary mouse ad-
ipocytes to show that intact PTH (1-84) as well as the N-terminal fragment (1-37) acutely stimulated lipolysis in
a dose-dependent manner, whereas the C-terminal fragment (38-84) was without lipolytic effect. The lipolytic
action of PTH was paralleled by phosphorylation of known protein kinase A (PKA) substrates, i.e. hormone-
sensitive lipase (HSL) and perilipin. The phosphorylation of HSL in response to PTH occurred at the known
PKA sites S563 and S660, but not at the non-PKA site S565. PTH-induced lipolysis, as well as phosphorylation
of HSL at S563 and S660, was blocked by both the PKA-inhibitor H89 and the adenylate cyclase inhibitor MDL-
12330A, whereas inhibitors of extracellular-regulated kinase (ERK), protein kinase B (PKB), AMP-activated pro-
tein kinase (AMPK) and Ca2+/calmodulin-dependent protein kinase (CaMK) had little or no effect. Inhibition of
phosphodiesterase 4 (PDE4) strongly potentiated the lipolytic action of PTH, whereas inhibition of PDE3 had no
effect. Our results show that the lipolytic action of PTH is mediated by the PKA signaling pathway with no or
minor contribution of other signaling pathways and, furthermore, that the lipolytic action of PTH is limited by si-
multaneous activation of PDE4. Knowledge of the signaling pathways involved in the lipolytic action of PTH is im-
portant for our understanding of how metabolic derangements develop in states of hyperparathyroidism,
including vitamin D deﬁciency.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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PDE1. Introduction
In addition to its classical role in the regulation of blood calcium
levels, there is accumulating evidence that parathyroid hormone
(PTH) exerts other actions thatmay be of relevance for thedevelopment
of extraskeletal disorders, including metabolic diseases. Positive
correlations between circulating levels of glucose and PTH have been
demonstrated in several studies [1–3]. An inverse relationship between
PTH levels and insulin sensitivity has also been observed and an in-
creased prevalence of diabetes is found in patients with high levels ofTGL, adipose triglyceride lipase;
extracellular-regulated kinase;
KA, protein kinase A; PKB, pro-
lated protein; PTH1R, PTH type
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. This is an open access article underPTH [4,5]. The association between insulin resistance and high levels
of PTH is further supported by intervention studies with parathyroidec-
tomy, which resulted in improved insulin sensitivity and normalized
blood glucose levels [6–8]. High levels of PTH are not only associated
with hallmarks of diabetes, but also with cardiovascular disease, as
shown in several observational studies [9–11].
Primary hyperparathyroidism is a common endocrine disorder,
especially among postmenopausal women. It is typically caused by the
presence of one or several benign adenomas in the parathyroid glands
secreting large amounts of PTH. Secondary hyperparathyroidism de-
velops in response to low calcium levels in the blood, most commonly
as a result of chronic kidney disease or vitamin D deﬁciency. During
the last decade, the literature describing the association between vita-
min D deﬁciency and metabolic disorders has grown immensely. It is
likely that the hyperparathyroidism that accompanies vitamin D deﬁ-
ciency contributes to, or even accounts for, some of themanymetabolic
derangements that characterize vitamin D deﬁcient states, as supported
by a couple of recent reports demonstrating that vitamin D status and
PTH levels are independent determinants of insulin sensitivity [12–14].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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blood calcium levels. Intact PTH is an 84 amino acid polypeptide (PTH
1-84) with a half-life of approximately 5 min in the circulation. It is
processed in the Kupffer cells of the liver to an N-terminal fragment
(PTH 1-37), with an even shorter half-life than intact PTH, and a C-
terminal fragment (PTH 38-84), with a half-life of several hours. All of
the classical biological activities of PTH are contained within the N-
terminal fragment, whereas the biological roles of the long-lived C-
terminal fragment is less known, but with regard to effects on bone
they appear to be opposite to those of PTH 1-37 (for a review see
[15]). PTH 1-84, as well as PTH 1-37, exerts their effects following bind-
ing to the PTH type 1 and 2 receptors (PTH1R and PTH2R), members of
the G-protein coupled receptor family [16], whereas PTH 38-84 binds to
a yet unknown receptor [8]. PTH-related protein (PTHrP), encoded by a
gene distinct from the PTH gene, is expressed in many normal and ma-
lignant tissues and causes hypercalcemia in certainmalignancies by act-
ing through the PTH1R [17].
Ectopic lipid deposition plays a critical role in the development of in-
sulin resistance, a hallmark of type 2 diabetes, and defects in adipocyte li-
polysis may account for ectopic lipid deposition through increased ﬂux of
fatty acids to non-adipose organs [18]. Several hormones and cytokines
have been shown to be involved in the regulation of lipolysis, with cate-
cholamines being the major lipolytic hormones and insulin being the
major anti-lipolytic hormone [19]. PTHhas been shown to act lipolytically
several decades ago in studies performed in humans as well as other pri-
mates [20–23]. Since these studieswere performed,much has been learnt
regarding both signaling pathways and lipases involved in the lipolytic
process [24]. Thus, the aim of this study was to describe the lipolytic ac-
tion of PTH on basis of the current knowledge of the molecular control
of lipolysis.
2. Materials and methods
2.1. Materials
C57Bl/6JBomTac mice were obtained from Taconic, Denmark.
Endothelin-1, isoprenaline hydrochloride, free glycerol reagent and glyc-
erol standard were from Sigma, fatty acid-free BSA from Roche
diagnostics GmbH (Mannheim, Germany) and amplex ultra red and
pre-cast Novex gels from Invitrogen (Carlsbad, CA, USA). PTH (1-37),
PTH (1-84) and PTHrP were from Bachem (Bubendorf, Switzerland)
and PTH (38-84) was obtained from GL Biochem (Shanghai, China).
MDL-12330A hydrochloride and KN-93 was from Calbiochem (San
Diego, CA, USA), H89 from Enzo lifescience (AH Diagnostics AB, Solna,
Sweden), MK 2206 from Active Biochem (Bonn, Germany), RO-20-1724
from Biomol Research Labs (Plymouth Meeting, PA, USA) and OPC3911
from Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). MRT 199665 was a
gift from Kristopher Clark, University of Dundee, UK. PD 0325901 was
provided by the Division of Signal Transduction Therapy (University of
Dundee, UK) and insulin was from Novo Nordisk A/S (Måløv, Denmark).
2.2. Antibodies
The antibody against totalHSL proteinwas an afﬁnity-puriﬁed rabbit
anti-rat HSL made in house against homogenous recombinant rat
HSL [25]. The phospho-speciﬁc antibodies against HSL (S563, S565
and S660), anti-PKB, anti-phospho ERK 1/2 S202/Y204, anti-ERK 1/2,
anti-ACC and anti-phospho ACC S79 were obtained from Cell Signaling
Technology (Beverly, MA). Anti-perilipin and anti-phospho perilipin
S522 were purchased from Vala Sciences (San Diego, CA, USA), anti-
phospho PKB S473 from Invitrogen (Carlsbad, CA, USA) and anti-
phospho adipose triglyceride lipase (ATGL) S406 from Abcam
(Cambridge, UK). Horseradish peroxidase (HRP)-conjugated sec-
ondary anti-mouse antibody was from GE Healthcare (Uppsala,
Sweden) and HRP-conjugated secondary anti-rabbit antibody was
from Pierce/Thermo Fisher Scientiﬁc (Waltham, MA, USA).2.3. Isolation of primary mouse adipocytes
Adipocytes were isolated by collagenase digestion from epididymal
adipose tissue of fed male C57BL/6JBomTac mice at the age of 9–
12 weeks. The preparation was performed according to [26] except
that the collagenase concentration was lowered from 1 mg/ml to
0.6 mg/ml and the incubation time was prolonged from 30 min to
75 min. The study was approved by the local Animal Ethics Committee,
Lund University, Sweden.
2.4. Lipolysis assay and sample preparation
Cells were diluted to a concentration of 5% in Krebs Ringer buffer
containing 25 mM Hepes, 1% fatty acid-free BSA, 200 nM adenosine
and 2 mM glucose. In experiments with inhibitors, cells were pre-
incubated with the respective inhibitor for 1 h (5 μM MK 2206, 3 μM
MRT 199665 or 0.2 μM PD 0325901) or 30 min (50 μM H89, 25 μM
MDL-12330A or 10 μM KN-93) at 37 °C in a shaking incubator at
60 rpm. Lipolysis was modulated by the addition of hormones as fol-
lows: PTH in concentrations ranging from 1 to 100 nM, insulin at
10 nM and isoprenaline at 20 nM. Cells were incubated at 37 °C in a
shaking incubator, 150 rpm, for different time periods as indicated. Ex-
periments were ended by incubating the cells on ice for 30 min before
an aliquot of the incubation media was taken for analysis of glycerol re-
lease used as an index of lipolysis. Glycerol was measured using a com-
mercially available kit with the addition of Amplex Ultra Red, a
hydrogen peroxide sensitive ﬂuorescence dye, described by Clark et al.
[27]. The rest of the media was discarded and cells were dissolved in
lysis buffer (50 mM Tris–HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 1%
NP40, 1 mM Na-orthovanadate, 40 mM NaF, 4 mM Na-pyrophosphate,
0.27 M sucrose, 500 mM DTT, 20 μg/ml leupeptin, 10 μg/ml antipain
and 1 μg/ml pepstatin), followed by a 5 min centrifugation at 13,000 g
to remove the fat layer.
2.5. Western blot analysis
An equal volume of lysate from each sample was subjected to Novex
pre-cast SDS-PAGE gels, 4–12%, and electrotransfered to nitrocellulose
membranes. The membranes were blocked in 2% BSA and 2% skimmed
milk powder for 30 min before probing with primary antibodies over-
night at 4 °C. Proteinswere detected using horseradish-peroxidase con-
jugated secondary antibodies together with a chemiluminescence
reagent. To conﬁrm equal loading, the blots were developed with the
antibody corresponding to the total protein for each phospho-speciﬁc
antibody.
2.6. Human protein atlas
Images of immunohistochemically stained tissue samples were
downloaded from the human protein atlas (www.proteinatlas.org)
[28,29] and used according to their data usage policy. mRNA-
sequencing data from the human protein atlas is based on The
Human Protein Atlas version 13 and Ensembl version 75.37 [30].
2.7. GTEx portal and GEO proﬁles database
mRNA-sequencing data (reads per kilobase of transcript per million
mapped reads (RPKM)) for PTH1R and PTH2R in human tissues was ex-
tracted from the data set; dbGaP accession number phs000424.v4.p1
downloaded 04/16/2015 [31] according to GTEx Data Release and
Publication Policy (v05-08-15; table updated May 8, 2015) (http://
www.gtexportal.org/home/). mRNA sequencing data (normalized
read counts (NRC)) for mouse (C57Bl/6J) epididymal adipose tissue
was extracted from the GEO proﬁles database [32]; GEO accession
GSE65976 [33].
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Sequences |P12272|37-177 and |P01270|32-115 (UniProtKB)
representing mature PTHrP and PTH, respectively, were compared
by pairwise alignment using the EMBOSS needle (global) and water
(local) programs [34].
2.9. Statistical analysis
Data are expressed as the mean ± S.D. Statistical signiﬁcance was
determined using unpaired two-tailed Student's t-tests, unless other-
wise indicated. The differences were considered statistically signiﬁcant
if p b 0.05. Statistical analysis was performed using Graph Pad Prism
version 6 software (GraphPad Software, La Jolla, CA, USA).
3. Results
3.1. PTH induces lipolysis inmouse adipocytes in a dose-dependentmanner
In order to describe the details of the lipolytic action of PTH, primary
mouse adipocytes were stimulated with PTH and, for comparison, the
non-selectiveβ-adrenergic agonist isoprenaline. As an index of lipolysis,
glycerol release into the medium was measured at three different
time points. PTH was used in three different molecular forms; intact
PTH (1-84), the N-terminal fragment (1-37) and the C-terminal frag-
ment (38-84). As shown in Fig. 1, the N-terminal fragment of PTH as
well as intact PTH stimulated lipolysis,whereas theC-terminal fragment
exhibited no lipolytic effect. A clear dose-dependency was observed
upon increasing the concentration from 1 to 10 nM, whereas little addi-
tional effect was observed upon raising the PTH concentration to
100 nM. In subsequent experiments, PTH (1-37) at a concentration of
10 nM was used. Compared to isoprenaline, PTH exerted a maximal
effect that was approximately 25% of the effect of an isoprenaline
concentration that in our hands gave maximal induction of lipolysis.Fig. 1. Lipolysis in response to stimulation with different PTH fragments. Primarymouse adipoc
of PTH (1-37) or (C) the C-terminal fragment of PTH (38-84) in increasing concentrations from
isoprenaline (iso) were used for comparison. Lipolysis was measured as glycerol concentrati
fragment. *p b 0.05, **p b 0.01, ***p b 0.001.3.2. Stimulation of mouse adipocytes with PTH (1-37) induces phosphory-
lation of known PKA targets
After having established that PTHacts lipolytically in our experimen-
tal system, we next went on to investigate if the lipolytic action of PTH
was paralleled by phosphorylation of known targets of protein kinase
A (PKA). The rationale for this was two-fold. First, PKA is known to
play a critical role in themolecular control of lipolysis through its phos-
phorylation of several of the key components, including perilipin 1,
which coats the adipocyte lipid droplets and thereby regulates lipase ac-
cess. It also phosphorylates hormone-sensitive lipase (HSL), which acts
in concert with adipose triglyceride lipase (ATGL) to hydrolyze stored
triacylglycerols (for a review see [35]). Secondly, PTH (1-37) is a ligand
of the G-protein coupled PTH receptors which activate PKA pathways in
target tissues. Perilipin 1 is known to be phosphorylated by PKA on at
least three serine residues, including S522 [36]. HSL is phosphorylated
at three serine residues by PKA, with S563 being the quantitatively
dominating site and S660 being the activity-controlling site [37]. As
shown in Fig. 2, stimulation of mouse adipocytes with PTH (1-37) in-
duced phosphorylation of PKA sites of both perilipin 1 and HSL. The
phosphorylation of HSL at S565, a site presumably phosphorylated by
AMP-activated protein kinase (AMPK) and with an anti-lipolytic role
[38], was reduced upon stimulation with PTH, as was also the case
upon stimulation with isoprenaline.
ATGL was recently described to be phosphorylated by PKA at S406
and phosphorylation of this site following β-adrenergic stimulation of
adipocytes was proposed to be coupled to a moderate increase in
ATGL activity and thus part of the molecular control of lipolysis [39].
Using a commercially available phospho-speciﬁc antibody against
S406 of ATGL, we found no evidence for phosphorylation of this site in
response to stimulation of mouse adipocytes with either isoprenaline
or PTH (data not shown). The reason for this discrepancy against pub-
lished data is not clear. However, we observed that the antibody in ad-
dition to ATGL also recognized a slightly larger and very abundant
phosphoprotein.ytes were isolated and stimulatedwith (A) intact PTH (1-84), (B) the N-terminal fragment
1 to 100 nM for 3, 10 or 30min. Untreated cells (control) and cells stimulatedwith 20 nM
on in the medium. The graphs represent mean values ± SD from three experiments per
Fig. 2. PTH stimulation of adipocytes results in phosphorylation of known PKA substrates.
Primary mouse adipocytes were isolated and stimulated with 10 nM PTH (1-37), 20 nM
isoprenaline or left untreated (control) for 30 min. Lipolysis was measured as glycerol
concentration in the medium. Aliquots of whole cell lysates were subjected to Western
blot analysis with antibodies recognizing perilipin phosphorylated at S522, total
perilipin, HSL phosphorylated at S563, S660 and S565 and total HSL. The graph
illustrates mean values ± SD from 22 experiments, shown together with representative
blots. ***p b 0.001.
207S. Larsson et al. / Cellular Signalling 28 (2016) 204–2133.3. Inhibition of PKA completely blocks the lipolytic effect of PTH
After having established that known PKA targets are phosphorylated
in response to PTH stimulation, we next investigated the effects of
blocking the PKA signaling pathway on the lipolytic effect of PTH. Prein-
cubating mouse adipocytes with H89, an inhibitor of PKA, was found to
completely prevent the lipolytic response to both PTH and isoprenalineFig. 3. Effect of inhibitors of PKA and adenylate cyclase on PTH-induced lipolysis and HSL phos
without 50 μM of the PKA inhibitor H89 (A) or for 60 min with 25 μM of the adenylate cyclase
isoprenaline for 30 min or left untreated. Lipolysis was measured as glycerol concentration in
antibodies recognizing HSL phosphorylated at S563, S660 and S565 and total HSL. The
representative blots. *p b 0.05, **p b 0.01, ***p b 0.001.(Fig. 3a). For both agonists, this was accompanied by a reduction of the
phosphorylation of the PKA sites of HSL (S563 and S660), whereas
phosphorylation of the non-PKA site (S565) tended to be increased. To
further validate the involvement of the PKA signaling pathway, we
used an inhibitor of adenylate cyclase, MDL-12330A. This inhibitor
was found to reverse the lipolytic response to both PTH and isoprena-
line, although not to the same extent as H89 (Fig. 3b). As for H89, the
reduction in lipolysis was accompanied by a reduction in the phosphor-
ylation of the PKA sites of HSL.
3.4. Inhibition of ERK, PKB, AMPK or CaMK has little or no effect on the
lipolytic action of PTH
Besides PKA, which is the key kinase in stimulation of lipolysis, other
kinases have been implicated in the molecular control of lipolysis. Fur-
thermore, at least in classical PTH target tissues, such as the kidney,
binding of PTH to its receptor couples not only to Gαs and thus the ade-
nylate cyclase-cAMP-PKA pathway, but also to Gαq, and thus signal
transduction pathways involving phospholipase C, diacylglycerol, inosi-
tol triphosphate and calcium-dependent kinases. To investigate a possi-
ble contribution by other kinases than PKA to PTH-induced lipolysis,
we used speciﬁc inhibitors to other relevant kinases. Extracellular-
regulated kinase (ERK) has been implicated in both cAMP-dependent
and cAMP-independent lipolysis and was in one study shown to phos-
phorylate HSL at a site (S600) distinct from the three sites alreadymen-
tioned [40]. Pre-treatment with the selective ERK inhibitor PD 0325901
had no effect on PTH-stimulated lipolysis (Fig. 4a). In line with this, we
observed no effects of PD 0325901 on the phosphorylation of HSL. Inhi-
bition of endothelin-induced phosphorylation of ERK served as a control
for functionality of the PD inhibitor in our experimental system. PKB is
believed to be a key kinase in the antilipolytic effect of insulin through
its phosphorylation and activation of PDE3B [41]. Pre-treatment
with the selective PKB inhibitor MK 2206 [42] had no effect on PTH-
induced lipolysis or phosphorylation of HSL, although it completely
blocked the insulin-induced phosphorylation of PKB (Fig. 4b). AMPK
activation has been shown to inhibit lipolysis and promote phosphory-
lation of HSL at S565, which prevents phosphorylation at the PKA
sites [38]. Phosphorylation of HSL at S565 by AMPK has also been
demonstrated in vitro [43]. Pre-treatment with the AMPK family inhib-
itor MRT 199665 tended to increase PTH-induced lipolysis (Fig. 4c).
At the same time, phosphorylation at S565 was blunted, whereasphorylation. Primary mouse adipocytes were isolated and pre-treated for 30 min with or
inhibitor MDL-12330A (B). Cells were then stimulated with 10 nM PTH (1-37) or 20 nM
the medium. Aliquots of whole cell lysates were subjected to Western blot analysis with
graph illustrates mean values ± SD from three experiments, shown together with
Fig. 4. Effects of inhibitors of ERK, PKB and AMPK on PTH-induced lipolysis and HSL phosphorylation. Primary mouse adipocytes were isolated and pre-treated with or without the
respective inhibitors. Cells were then stimulated with 10 nM PTH (1-37) for 30 min or left untreated. Lipolysis was measured as glycerol concentration in the medium. Aliquots of whole
cell lysates were subjected to Western blot analysis with antibodies recognizing HSL phosphorylated at S660, S563 and S565 and total HSL. (A) Pre-treatment with 0.2 μM of ERK
inhibitor PD 0325901 for 60 min. Inhibition of phosphorylation of ERK in response to stimulation with 10 nM endothelin-1 served as positive control for PD 0325901, (B) Pre-treatment
with 5 μM of the PKB inhibitor MK 2206 for 60 min. Phosphorylation of PKB in response to stimulation with 10 nM insulin served as positive control for MK 2206, (C) Pre-treatment with
3 μM of the AMPK family inhibitor MRT 199665 for 60 min. Inhibition of phosphorylation of acetyl-CoA carboxylase A (ACC) served as positive control for MRT 199665. (D) Pre-
treatment with 10 μM of the CaMK inhibitor KN-93 for 30 min. The graph illustrates mean values ± SD from 3–4 experiments, shown together with representative blots. *p b 0.05.
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inhibitor was conﬁrmed by its ability to markedly reduce phosphoryla-
tion of acetyl-CoA carboxylase, a known AMPK substrate. PTH induces
activation of calcium-dependent kinases and calcium/calmodulin-
dependent protein kinase (CaMK) has been shown to phosphorylate
S565 of HSL, thereby preventing phosphorylation of the PKA sites [43].
Moreover, increasing the intracellular concentration of calcium has
been shown to inhibit isoprenaline-induced lipolysis, presumably
through activation of PDE and thereby reduction of cAMP levels and
HSL phosphorylation [44]. Pre-treatment with the selective CaMK in-
hibitor KN-93 had no effect on PTH-induced lipolysis or phosphoryla-
tion of HSL (Fig. 4d). Taken together, the results from the experiments
with the different inhibitors indicate that PTH stimulates lipolysismain-
ly via activation of the cAMP-PKA pathwaywith no or little contribution
from other kinases/pathways.
3.5. Expression of PTH receptors in adipose tissue
As shown in the lipolysis experiments displayed in Figs. 1 and 2,
the maximal PTH-induced lipolysis was about 25% of the maximalisoprenaline-induced lipolysis. One possible explanation for this is that
the number of PTH receptors is low. According to data deposited in
the GTEx Portal and the Human Protein Atlas, the expression of PTH1R
mRNA and protein is medium in human adipose tissue (Table 1 and
Fig. 5a–b), whereas the expression of PTH2R is below detectable levels
(Table 1 and Fig. 5c). With regard to data for mouse, a search of the
GEO Proﬁles database showed that PTH1R is expressed inmouse epidid-
ymal adipose tissue, whereas the expression of PTH2R falls under the
detection limit (Table 2).
3.6. Potentiation of PTH-induced lipolysis by inhibition of PDE4
Phosphodiesterases (PDEs), subdivided into 11 families, modulate
the duration and intensity of the intracellular response to cAMP by hy-
drolyzing the cyclic nucleotide. Different cells showdifferent expression
patterns of PDEs and the different PDEs exhibit different intracellular
distribution and catalytic and regulatory properties. PDE3B and PDE4
are the main PDEs expressed in adipocytes, the former having a key
role in mediating insulin-induced inhibition of catecholamine-induced
lipolysis. One possibility is that the difference in lipolytic capacity
Table 1
Protein and mRNA expression of PTH1R and PTH2R in human tissues and cells based on mRNAseq and immunohistochemical detection. Data is derived from the Human Protein Atlas,
www.proteinatlas.org (in accordance with their data usage policy).
Pth1r Pth2r
Tissue Cells aWhole tissue mRNA (FPKM) Protein level aWhole tissue mRNA (FPKM) Protein level
Adipose tissue Adipocytes 14,6 ± 0,8 Medium 1,5 ± 0,7 ND
Fibroblasts Medium ND
Adrenal gland Glandular cells 21,9 ± 7,5 High 0,4 ± 0,3 ND
Brain Neuronal cells 4,4 ± 1,3 Medium 1,5 ± 1,3 ND
Colon Endothelial cells 2,3 ± 1,63 Medium 0,1 ± 0,1 High
Glandular cells High ND
Duodenum Glandular cells 0,9 ± 0,2 Medium 1,0 ± 0,2 ND
Esophagus Epithelial cells 1,6 ± 0,9 High 0,1 ± 0,1 ND
Gallbladder Glandular cells 3,5 ± 2,4 High 0,6 ± 0,5 ND
Heart Myocytes 4,2 ± 1,8 Medium 0,0 ND
Kidney Glomeruli 183,1 ± 69,2 Medium 23,3 ± 5,3 High
Tubules Medium ND
Liver Bile duct 9,3 ± 3,4 Low 0,8 ± 0,4 ND
Hepatocyte Low ND
Pancreas Islets of Langerhans 1,2 ± 0,8 Low 0,2 ± 0,1 Medium
Exocrine glandular cells Medium High
Skin Melanocytes 2,1 ± 1,0 Medium 0,0 ND
Fibroblasts Medium ND
Keratinocytes Medium ND
Epidermal cells High ND
Small intestine Glandular cells 1,2 ± 0,4 Low 0,1 ± 0,1 ND
Stomach Glandular cells 1,2 ± 0,9 Medium 0,3 ± 0,3 Low
Testis Ducts 3,2 ± 1,4 Medium 0,9 ± 0,4 ND
Leydig cells High ND
Thyroid gland Glandular cells 0,8 ± 0,5 Medium 0,0 ND
FPKM 0–1 = not detected (ND), 1–10 = low, 10–50 =medium and N50 = high. Fragments per kilobase of exon per million fragments mapped (FPKM).
a RNAseq was performed on mRNA prepared from whole tissue samples.
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of PDE associated with the respective signaling complexes. Thus, to
test the ability of PDE3 and PDE4 to restrain cAMP signaling initiated
by the respective hormones, we utilized selective inhibitors for PDE3
and PDE4. Pre-treatment with OPC3911, a selective inhibitor of PDE3,
was found to have no effect on neither PTH-induced nor isoprenaline-
induced lipolysis (Fig. 6a). Pre-treatment with RO-20-1724, a selective
PDE4 inhibitor, on the contrary, was found to potentiate PTH-induced li-
polysis by more than 100%. Also isoprenaline-induced lipolysis tended
to be potentiated by RO-20-1724, although to a much lower degree
and not statistically signiﬁcant. In the presence of RO-20-1724, the lipo-
lytic response to PTH was 56% of that in response to isoprenaline, com-
pared to 27% in the absence of RO-20-1724 (Fig. 6a). Thus, both PTH and
isoprenaline induce signaling pathways leading up to simultaneous
cAMP formation and breakdown. However, the balance between these
two pathways is different for the two agonists, with isoprenaline acting
mainly lipolytically, whereas PTH appears to activate the two pathways
to a similar extent.
Several studies have shown that the lipolytic effect exerted by iso-
prenaline, and other β-adrenergic agonists, can be completely blocked
by insulin and that activation of PDE3B is themajormechanisms under-
lying this effect. Insulin, at concentrations found to completely block
isoprenaline-induced lipolysis, was found also to completely block
PTH- induced lipolysis. In both cases, the anti-lipolytic effect of insulin
was paralleled by decreased phosphorylation of HSL (Fig. 6b). For both
agonists, pre-treatment with OPC3911 blocked the anti-lipolytic effect
of insulin, whereas RO-20-1724 did not (Fig. 6). Thus, PTH-induced
lipolysis can be blocked by insulin-mediated activation of PDE3B, as
is the case for isoprenaline-induced lipolysis, shown both here and
previously [41].
3.7. Parathyroid hormone-related protein (PTHrP) exerts the same lipolytic
action as PTH (1-37)
During the course of this work, PTHrP was shown to be involved in
mediating energy wasting in fat tissues and to contribute to cancercachexia [45]. Furthermore, using primary white and brown adipocytes
differentiated from the inguinal stromal-vascular fraction of male mice,
it was shown that PTHrP, as well as PTH, induced PKA-mediated
phosphorylation of HSL that could be blocked byH89. PTHrP has a glob-
al sequence identity to PTH of 14% and a local sequence identity of 34.4%
within the ﬁrst 32 amino acids of the N-terminal fragment (Fig. 7a). To
conﬁrm that PTHrP acts lipolytically, we employed it in our experimen-
tal system and found it to behave identically to PTH (1-37) with regard
to lipolytic potency at 10 nM (Fig. 7b).
4. Discussion
To the best of our knowledge this is the ﬁrst study describingmolec-
ular details of the lipolytic action of PTH. PTH was found to exert its
lipolytic effect through PKA-mediated phosphorylation of HSL, with
minor or no contribution from other kinases. The maximal lipolytic
effect of PTH was about 25% of that of isoprenaline, a non-selective β-
adrenergic agonist. Simultaneous activation of the cAMP-PKA pathway
and the anti-lipolytic pathway leading to activation of PDE4, rather
than low expression of PTH receptors, explains the lowmaximal lipolyt-
ic effect of PTH, since the lipolytic effect of PTH in the presence of RO-20-
1724, a PDE4 inhibitor, was comparable to that of isoprenaline.
The conclusion that PTH exerts its lipolytic action via activation of
the cAMP-PKA pathway with no or minor contribution from other sig-
naling pathways is based on the ﬁnding that inhibitors of the cAMP-
PKA pathway blocked the lipolytic action of PTH, whereas inhibitors of
other kinases implicated in lipolysis regulation or PTH signaling, i.e.
ERK, PKB, AMPK, and CaMK, did not. In fact, inhibition of AMPK tended
to stimulate basal lipolysis as well as lipolysis induced by both PTH and
isoprenaline. This was paralleled by complete abolishment of the phos-
phorylation of HSL at S565 and increased phosphorylation of the PKA
sites (S563 and S660), well in line with the established anti-lipolytic
role of S565 [38]. In classical PTH target tissues, PTH induces activation
of calcium-dependent kinases and calcium/calmodulin-dependent pro-
tein kinase (CaMK) has been shown to phosphorylate S565 of HSL,
thereby preventing phosphorylation of the PKA sites [43]. The fact that
Fig. 5. Expression of PTH receptors in adipose tissue. (A) Representative images of human tissues stained using antibodies speciﬁc for PTH1R. Imageswere downloaded fromwww.proteinatlas.
org and used according to their data usage policy. (B) Pthr1 and (C) Pthr2mRNA expression levels in human tissues based onmRNAseq data derived from the GTEx portal (in accordancewith
their data usage policy). Data is presented as Reads Per Kilobase of transcript per Million mapped reads (RPKM) ± standard deviation (log scale), n = 22–142 depending on tissue.
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Table 2
RNAseq expression data from epididymal mouse adipose tissue
(C57Bl/6J), n = 3a.
Protein
Normalized
read counts
PTH1R 111 ± 13
PTH2R 1 ± 1
Insulin receptor 4167 ± 1648
β-Adrenergic receptor 3 6405 ± 2609
PKA-catalytic subunit α 1050 ± 17
PKA-catalytic subunit β 1170 ± 78
a Datawas extracted fromGEOaccessionGSE65976 [1]. Data is presented
as normalized read counts ± standard deviation derived from Raw Htseq-
count reads.
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suggests that CaMK is not induced in response to PTH stimulation of ad-
ipocytes and/or that CaMK does not phosphorylate HSL in vivo. In bone,
and especially kidney, PTH has been shown to mediate some of its
effects via binding to Gq-coupled receptors, which activate signaling
cascades involving phospholipase C, the second messengers inositol-
3-phosphate, calcium and diacylglycerol and protein kinase C [46,47].
Thus, although PTH appears to mediate effects on lipolysis mainly
through coupling to Gα and thus activation of cAMP-PKA signaling
cascades, minor contributions from signaling through Gq cannot be
excluded.Fig. 6. Effects of inhibitors of PDE3B and PDE4 on PTH-induced lipolysis and HSL
phosphorylation. Primary mouse adipocytes were isolated and pre-treated with or
without 10 μM OPC3911 or 10 μM RO-20-1724 for 30 min. Cells were then stimulated
with 10 nM PTH (1-37), 20 nM isoprenaline, or 10 nM insulin for 30 min or left
untreated. Lipolysis was measured as glycerol concentration in the medium (A).
Aliquots of whole cell lysates were subjected to Western blot analysis with antibodies
recognizing HSL phosphorylated at S660, S563 and S565 and total HSL (B). The graph
illustrates mean values ± SD from three experiments, shown together with
representative blots. *p b 0.05, **p b 0.01, ***p b 0.001.Data deposited in the GTEx Portal and the Human Protein Atlas
showed that PTH1R is expressed at medium levels in human adipose
tissue, whereas PTH2R is expressed at low or non-detectable levels
with a good correlation between mRNA and protein data. These data
are in disagreement with a recently published paper on the expression
of different G-protein coupled receptors in human adipose tissue, show-
ing that both receptors type are expressed at only trace levels [48]. The
reason for the discrepancy is not known but it should be pointed out
that the data deposited in GTEx portal and human protein atlas is
based on RNA sequencing data and immunohistochemical analyses, re-
spectively, whereas the data in the paper by Amisten et al. [48] is based
on mRNA quantiﬁcation by qPCR. mRNA sequencing data deposited in
the GEO Proﬁles Database showed that PTH1R is expressed also in
mouse epididymal adipose tissue, whereas the expression of PTH2R is
below the detection limit. Since the data in the GEO Proﬁles Database
is from independent experiments, no comparisons to the expression
levels in other mouse tissues can be made.
Since the data in the GTEx Portal and the Human Protein Atlas sug-
gested that at least PTH1R is expressed at signiﬁcant levels in adipose
tissue, we next considered that the reason for the lowmaximal lipolytic
effect of PTH was explained by properties of the PTH signaling rather
than a low abundance of PTH receptors. In fact, blocking the activity of
one of the major phosphodiesterases in adipose tissue, i.e. PDE4, signif-
icantly increased the lipolytic action of PTH, whereas it had a minor ef-
fect on the lipolytic action of isoprenaline. This indicates that the
balance between lipolytic and anti-lipolytic action is very different for
isoprenaline and PTH, with isoprenaline signaling predominantly
through the lipolytic, cAMP-generating pathway, whereas PTH to a
much larger extent activates also an anti-lipolytic, cAMP-hydrolyzing
pathway. Thus, PTH exerts both lipolytic and anti-lipolytic actions and
only in the presence of a PDE4 inhibitor is its full lipolytic action ob-
served. The lipolytic effect of PTH can be antagonized by insulin in a
PDE3B-dependent manner, as is the case also for isoprenaline.
The PTH levels in plasma are under normal physiological conditions
in the picomolar range, and only under pathological conditions do they
approach nanomolar concentrations. Secondary hyperparathyroidism
as a result of severe kidney failure can be accompanied by very high
levels of PTH, whereas secondary hyperparathyroidism, due to vitamin
D deﬁciency without any kidney disease, and also primary hyperpara-
thyroidism, due to the presence of adenomas of the parathyroid glands,
usually are accompanied by more moderate elevations of PTH levels. In
addition to elevated levels of PTH in different states of hyperparathy-
roidism, high, or even very high, levels of PTHrP are observed in
tumor diseases, where it contributes to the development of cachexia,
as recently demonstrated [45]. PTHrP binds to PTH1R and signals
through the cAMP-PKA pathway, as shown both previously [45] and
in the present study. In agreementwith this, the lipolytic action exerted
by PTHrPwas comparable to that of PTH, as shown in the present study.
Elevated PTH levels may contribute to a metabolic phenotype in the
different forms of hyperparathyroidism, where vitamin D deﬁciency
presumably is the most prevalent condition accompanied by elevated
PTH levels. Several clinical studies demonstrate that vitamin D status
and PTH levels are independent determinants of insulin sensitivity
with increased PTH levels being associated with decreased insulin sen-
sitivity [4–8]. The mechanisms whereby PTHmay decrease insulin sen-
sitivity are not known, but one possible mechanism is that chronically
elevated PTH levels, via its lipolytic action, lead to increased ﬂux of
fatty acid from adipose tissue and thereby ectopic lipid deposition,
which plays a critical role in the development of insulin resistance
[34]. Vitamin D deﬁciency and accompanying secondary hyperparathy-
roidism is common among obese individuals, possibly due to trapping
of vitamin D in adipose tissue [16]. Obese individuals also exhibit
decreased levels of PDE4 activity in subcutaneous and, even more pro-
nounced, omental adipocytes compared to normal weight individuals
[49]. Whether this is reﬂected in a more pronounced lipolytic action
of PTH in obese than normal weight individuals is not known, but
Fig. 7. Lipolysis in response to stimulation with PTHrP. (A) Alignment of intact PTH and PTHrP. The N-terminal region of PTHrP shows sequence similarities with PTH. (B) Primary mouse
adipocyteswere isolated and pre-treatedwith orwithout the PKA inhibitor H89 for 30min. Cellswere then stimulatedwith 10nMPTH (1-37) or 10 nMPTHrP for 30min or left untreated.
Lipolysiswasmeasured as glycerol concentration in themedium. Aliquots ofwhole cell lysateswere subjected toWestern blot analysiswith antibodies recognizingHSL phosphorylated at
S563, S660 and S565 and total HSL. The graph illustrates mean values ± SD from two experiments, shown together with representative blots.
212 S. Larsson et al. / Cellular Signalling 28 (2016) 204–213constitutes an interesting question for future studies. Besides obesity,
pharmacological inhibition of PDE4, currently in clinical use for mainte-
nance treatment of chronic pulmonary obstructive disease [50], is an-
other condition where the lipolytic action of PTH is potentiated. Again,
whether this is the case in the clinical situation remains to be clariﬁed.
5. Conclusions
In summary, we conclude that PTH induces lipolysis in primary
mouse adipocytes via activation of the cAMP-PKA pathway, with no or
little contribution from other kinases. The lipolytic action of PTH is
weak compared to the non-selective β-adrenergic agonist isoprenaline.
However, the lipolytic action of PTH is potentiated bymore than 100% in
the presence of a PDE4 inhibitor,whereas the lipolytic action of isopren-
aline is not affected by the PDE4 inhibitor. The metabolic impact of ele-
vated PTH levels is not yet understood. However, our ﬁndings suggest
that in situations of elevated PTH levels in combination with decreased
PDE4 activity in adipose tissue, such as in vitamin D deﬁciency in com-
binationwith obesity and/or treatmentwith PDE4 inhibitors, PTH could
contribute to increased fatty acid ﬂux from adipose tissue, which in turn
may lead to the development of insulin resistance and other metabolic
derangements.
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